Psoriasis: risankizumab shows good long-term efficacy in phase 3 RCT

  • Blauvelt A & al.
  • JAMA Dermatol
  • 8 Apr 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Risankizumab was associated with improved efficacy compared with placebo at 16 weeks in this phase 3 randomized controlled trial (RCT).
  • It also is associated with improved efficacy compared with treatment withdrawal at 1 and 2 years for patients with moderate to severe plaque psoriasis.

Why this matters

  • Risankizumab appears to represent a promising method for maintaining clinical efficacy in these patients.

Key results

  • At week 16, vs placebo, risankizumab was associated with higher rates of:
    • ≥90% improvement in the Psoriasis Area and Severity Index: 73.2% vs 2.0% (P<.001>
    • Static Physician’s Global Assessment (sPGA) score 0/1: 83.5% vs 7.0% (P<.001>
  • Compared with treatment withdrawal, risankizumab was associated with higher rates sPGA score 0/1 at:
    • 1 year: 87.4% vs 61.3%.
    • 2 years: 81.1% vs 7.1% (P<.001 for both>
  • Risankizumab and placebo were associated with similar rates of treatment-emergent adverse events at week 16 (45.7% vs 49.0%).

Study design

  • 507 patients with moderate to severe plaque psoriasis were randomly assigned to risankizumab (n=407) or placebo (n=100).
  • At week 28, a total of 336 responders were randomly allocated to risankizumab (n=111) or treatment withdrawal (n=225).
  • Funding: AbbVie, Boehringer Ingelheim.

Limitations

  • Lack of QoL measurements.